Barclays analyst Leon Wang downgraded CinCor Pharma (CINC) to Equal Weight from Overweight with a price target of $31, up from $22, after the company enter into an agreement to be acquired by AstraZeneca (AZN). The anlayst thinks the contingent value right is worth $5 per share.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CINC: